Scarica l'app Stockscreener
73.08
1.12%
0.81
Dopo l'orario di chiusura:
72.56
-0.52
-0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$72.27
Aprire:
$72.35
Volume 24 ore:
3.32M
Relative Volume:
0.63
Capitalizzazione di mercato:
$28.13B
Reddito:
$4.52B
Utile/perdita netta:
$720.70M
Rapporto P/E:
40.67
EPS:
1.7968
Flusso di cassa netto:
$1.06B
1 W Prestazione:
+4.37%
1M Prestazione:
+3.32%
6M Prestazione:
-10.52%
1 anno Prestazione:
-18.20%
Intervallo 1D:
$72.04
$73.37
Intervallo di 1 settimana:
$69.81
$73.37
Portata 52W:
$54.11
$91.87
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
73.08 | 27.81B | 4.52B | 720.70M | 1.06B | 1.7968 |
|
ABT
Abbott Laboratories
|
112.21 | 195.08B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
380.23 | 142.61B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
96.86 | 125.10B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
74.58 | 112.29B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.78 | 45.80B | 6.07B | 1.06B | 799.60M | 1.8527 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Yahoo Finance
SENS Eversense 365 Integrated With twiist Gains Full Availability - TradingView
The 5 Most Interesting Analyst Questions From DexCom’s Q4 Earnings Call - The Globe and Mail
The Strong Earnings Posted By DexCom (NASDAQ:DXCM) Are A Good Indication Of The Strength Of The Business - simplywall.st
The 5 Most Interesting Analyst Questions From DexCom's Q4 Earnings Call - Finviz
P/E Ratio Insights for DexCom - Benzinga
What Wall Street predicts for DexCom Inc. stock pricePortfolio Gains Summary & Free Real-Time Volume Trigger Notifications - mfd.ru
Dexcom G6 Glucose Monitor Lawsuit Claims Manufacturer’s Device Modifications Resulted in Teen’s Death - AboutLawsuits.com
Dexcom Stock After Volatility: Is This High-Growth Medtech Now Mispriced? - AD HOC NEWS
What DexCom (DXCM)'s Margin Beat And Reaffirmed 2026 Outlook Means For Shareholders - simplywall.st
The DexCom, Inc. (NASDAQ:DXCM) Yearly Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook - Bitget
DexCom Earnings Call Highlights Margin Rebound, Growth - The Globe and Mail
Is DexCom Inc. in a consolidation phaseJuly 2025 Final Week & Weekly Breakout Watchlists - mfd.ru
DexCom (DXCM) Margin Expansion To 17.9% Reinforces Bullish Earnings Narratives - Sahm
DexCom’s AI Stelo Upgrade Faces Valuation Questions After Share Declines - Sahm
DexCom Expands G7 And Stelo To Deepen CGM Ecosystem Engagement - Yahoo Finance
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth - sharewise.com
DexCom (DXCM) Maintains Buy Rating Despite Lowered Price Target - GuruFocus
Key facts: DexCom reports $2.8B profit; Wells Fargo cuts price target - TradingView
Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday? - Benzinga
Why Is DexCom (DXCM) Stock Rocketing Higher Today - Finviz
Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations - Yahoo Finance
Dexcom seeks expanded Medicare coverage of CGMs for Type 2 diabetes - MedTech Dive
Barclays Updates Rating on DexCom (DXCM) with Slight Price Targe - GuruFocus
DexCom (NASDAQ:DXCM) Stock Price Up 8.4% on Earnings Beat - MarketBeat
Wells Fargo & Company Has Lowered Expectations for DexCom (NASDAQ:DXCM) Stock Price - MarketBeat
DXCM Q4 Deep Dive: New Product Launches and International Strategy Drive Outlook - Finviz
DexCom, Inc. (NASDAQ:DXCM) Q4 2025 Earnings Call Transcript - Insider Monkey
DexCom (NASDAQ:DXCM) Price Target Raised to $90.00 - MarketBeat
DexCom, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts DexCom Price Target to $83 From $86, Maintains Outperform Rating - marketscreener.com
Baird Adjusts DexCom Price Target to $87 From $82, Maintains Outperform Rating - marketscreener.com
Mizuho Securities Adjusts DexCom Price Target to $90 From $78, Maintains Outperform Rating - marketscreener.com
Wells Fargo Adjusts DexCom Price Target to $85 From $93, Maintains Overweight Rating - marketscreener.com
7 Analysts Have This To Say About DexCom - Benzinga
DexCom (DXCM) Gets a Reaffirmed "Buy" Rating from BTIG | DXCM St - GuruFocus
Stifel reiterates Buy rating on DexCom stock, maintains $85 price target By Investing.com - Investing.com South Africa
DexCom (NASDAQ:DXCM) Exceeds Q4 CY2025 Expectations - The Globe and Mail
Stifel reiterates Buy rating on DexCom stock, maintains $85 price target - Investing.com
DexCom Expands Stelo AI Features As Consumer Glucose Strategy Evolves - Sahm
Decoding DexCom Inc (DXCM): A Strategic SWOT Insight - GuruFocus
DexCom Inc (DXCM) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Dexcom Q4 2025 presentation slides: double-digit growth amid margin expansion - Investing.com South Africa
DexCom Q4 2025 Earnings Call Insights - Intellectia AI
Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results - BioSpace
DexCom (DXCM) Surpasses Q4 2025 Earnings Expectations - GuruFocus
DexCom (DXCM) Q4 2025 Earnings Call Transcript - The Globe and Mail
DexCom (NASDAQ:DXCM) Announces Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Dexcom (DXCM) Reports Strong Q4 Revenue with Promising Future Ou - GuruFocus
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):